Conceptual
Login

Esomeprazole: Handedness and Sulfide Oxidation to a Sulfoxide in Organic Chemistry

Molecular chirality (handedness) can arise at atoms other than a tetrahedral carbon: pyramidal sulfur becomes a stereocenter when a sulfide is oxidized to a sulfoxide, because the lone pair occupies a fixed position and the sulfur does not invert, producing two enantiomers (a racemate) when the reaction has no stereochemical bias. Because a chiral drug interacts with a homochiral biological target (an enzyme), the two enantiomers can form diastereomeric complexes with that target and therefore behave differently — a "chiral switch," converting a racemic drug to a single-enantiomer drug, is a strategy pharmaceutical companies use to potentially improve or re-patent an existing therapy. Establishing whether a chiral switch is genuinely superior, rather than just commercially motivated, requires the framework of clinical pharmacology: phased human trials (Phase 1 safety, Phase 2 efficacy, Phase 3 large-scale confirmatory, Phase 4 post-marketing surveillance), FDA approval tied to specific dose and indication, biostatistical comparison of dose-matched trial arms, and the distinction between on-label and off-label prescribing.